Drug Trial Radar · NCT00266487
The Norwegian Vitamin Trial (NORVIT)
Last checked: Nov 20, 2026Latest source record: May 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,750
Actual
Start
Dec 1998
Primary completion
Not stated
Study completion Mar 2004
Sponsor
- Lead sponsor
- University of TromsoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Research Council of Norway; The Council on Health and Rehabilitation, Norway; The Norwegian Council on Cardiovascular Disease; The Royal Norwegian Ministry of Health; The International Federation of Red Cross and Red Crescent Societies; Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway
- First posted
- Dec 16, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine whether the lowering of blood homocysteine levels by treatment with B vitamins can prevent cardiovascular disease
Conditions
- Acute Myocardial Infarction
Interventions
Folic acidDrug
Vitamin B12Drug
Vitamin B6Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary end point was a composite of
- nonfatal myocardial infarction,
- fatal myocardial infarction,
- nonfatal stroke,
- fatal stroke, and
- sudden death attributed to coronary heart disease.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Community Medicine, University of Tromsø
Tromsø, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.